"NCT Number";"Study Title";"Study URL";"Acronym";"Study Status";"Study Results";"Conditions";"Interventions";"Primary Outcome Measures";"Secondary Outcome Measures";"Other Outcome Measures";"Sponsor";"Collaborators";"Sex";"Age";"Phases";"Enrollment";"Funder Type";"Study Type";"Study Design";"Other IDs";"Start Date";"Primary Completion Date";"Completion Date";"First Posted";"Results First Posted";"Last Update Posted";"Locations";"completion_date";"completion_year";"completion_month";"eligible_year";"year_bin";"enrollment_bin"
"NCT00449592";"Oral Zinc Therapy for the Prevention of Mucositis";"https://clinicaltrials.gov/study/NCT00449592";"";"COMPLETED";"NO";"Mucositis";"DRUG: Zinc|DRUG: Placebo";"Maximal Mucositis grade, day -7 to day +21 or discharge day";"Duration of maximal mucositis grade, day -7 to day +21 or discharge day|Overall duration of mucositis, day -7 to day +21 or discharge day|Duration of severe neutropenia, day -7 to day +21 or discharge day|Duration of febrile neutropenia, day -7 to day +21 or discharge day";"";"Sheba Medical Center";"";"ALL";"ADULT, OLDER_ADULT";"PHASE4";40;"OTHER_GOV";"INTERVENTIONAL";"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION";"SHEBA-06-4196-MKM-CTIL";"2007-04";"2008-09";"2008-09";2007-03-20;NA;2008-10-03;"Division of Hematology and Bone Marrow Transplantation, Sheba Medical Center, Ramat Gan, Israel";"2008-09";2008;9;TRUE;"2005-2009";"1-99"
"NCT00711412";"Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer";"https://clinicaltrials.gov/study/NCT00711412";"";"COMPLETED";"YES";"Esophageal Cancer";"DRUG: Induction Therapy - Capecitabine|DRUG: Induction Therapy - Oxaliplatin|DRUG: Combination Therapy - Capecitabine|DRUG: Combination Therapy - Oxaliplatin|RADIATION: Combination Therapy - Radiation|PROCEDURE: Evaluation for response and surgery";"Determine Pathologic Complete Response, Pathologic response will be assessed semiquantitatively irrespective of lymph node status based on the estimated percentage of residual carcinoma in relation total carcinoma area, including amount of radiotherapy-induced tissue injury, in mural histologic sections.

Pathologic response will be defined as:

P0: 0% residual cancer P1: 1% to 50% residual cancer P2: more than 50% residual cancer, At time of surgery";"Clinical Response Rate, Clinical response Rate will be expressed as the proportion of patients demonstrating a complete and/or partial response based on all evaluable patients treated.Clinical response will be evaluated according to Response Evaluation Criteria In Solid Tumors 1.0 (RECIST) .

Complete Response (CR) is defined as the disappearance of all target lesions Partial Response (PR) is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions,taking as reference the baseline sum LD, four to six weeks following completion of 4 cycles (1 cycle = 21days) of chemotherapy treatment and prior to surgery|Recurrence Rate, Recurrence rate will be defined as disease recurrence, progressive disease or death. Patients will be followed for disease recurrence or death until the end of the study., From the time of start of treatment until first documentation of disease recurrence, progression or death, whichever comes first until the end of the study, a maximum of 6 years and 7 months.|Time to Progression, Time to Progression will be measured as time from the first day of therapy until death, disease progression or last contact., From start of first treatment until time of first documentation of progression of disease or death, whichever comes first, until the study closes, up to a maximum of 6 years and 7 months.|Patterns of Failure, At time of surgery|Toxicity Profile, Toxicity will be assessed at the beginning of every cycle during chemotherapy for a total of 4 cycles (1 cycle =21 days) and then 30 days post last dose of chemotherapy. All toxicities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (CTCAE 3.0)

In general adverse events (AEs) will be graded according to the following:

Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE

Only incidents of AEs determined to be related to chemotherapy are recorded here., During chemotherapy treatment and up to 30 days post-last dose of chemotherapy.|Correlate Proteomic and Pharmacologic Characteristics With Prognosis and Response to Therapy., At time of sugery";"";"Northwestern University";"";"ALL";"ADULT, OLDER_ADULT";"PHASE2";44;"OTHER";"INTERVENTIONAL";"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT";"NU 05I2|STU00006779";"2006-05-31";"2009-05-29";"2013-01-30";2008-07-08;2018-07-18;2018-07-18;"Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, 60611-3013, United States";"2009-05-29";2009;5;TRUE;"2005-2009";"1-99"
"NCT00218920";"Effective Training in Overweight and Obese People";"https://clinicaltrials.gov/study/NCT00218920";"";"COMPLETED";"NO";"Obesity|Overweight";"BEHAVIORAL: Strength training|BEHAVIORAL: continuous moderate-intensity aerobic training|BEHAVIORAL: high-intensity interval aerobic training";"Body weight, 12 weeks|Aerobic capacity, 12 weeks|Endothelial function, 12 weeks";"Molecular markers in fat and skeletal muscle biopsies for the effects of exercise training, 12 weeks";"";"Norwegian University of Science and Technology";"";"ALL";"ADULT, OLDER_ADULT";NA;40;"OTHER";"INTERVENTIONAL";"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE|Primary Purpose: TREATMENT";"4-2005.542";"2005-09";"2008-01";"2008-01";2005-09-22;NA;2017-10-16;"Norwegian University of Science and Technology, Trondheim, 7489, Norway";"2008-01";2008;1;TRUE;"2005-2009";"1-99"
"NCT01502553";"Clinical Study of Blood Pressure Monitor in Conformance With the ANSI/AAMI SP10";"https://clinicaltrials.gov/study/NCT01502553";"BPM_S";"COMPLETED";"NO";"Hypertension";"DEVICE: Comparison Test to Yuyue Medical BP Meter, YYBP-212";"Verify the accuracy of measure functions of device, Verify the accuracy of device if meet the requirements of ANSI/AAMI SP10 when it measure Systolic \& Diastolic blood pressure., 10 days";"";"";"Leo Wang";"BTS International";"ALL";"ADULT, OLDER_ADULT";NA;95;"OTHER";"INTERVENTIONAL";"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC";"Trans 2011004|BTS-TRANS04";"2011-10";"2011-10";"2011-11";2011-12-30;NA;2011-12-30;"Zhongshan City People's Hospital, Zhongshan, Guangdong, 528403, China";"2011-10";2011;10;TRUE;"2010-2014";"1-99"
"NCT02766036";"Propolis Effects in Patients With Chronic Kidney Disease";"https://clinicaltrials.gov/study/NCT02766036";"";"COMPLETED";"NO";"Chronic Kidney Diseases";"DRUG: Propolis|DRUG: Placebo";"Reducing Proteinuria, Reduction from baseline proteinuria., One year";"Protection of the glomerular filtration rate, Maintaining glomerular filtration rate or inferior reduction to 5 ml per minute per 1.73 m2 of body-surface area from baseline., One year";"";"University of Sao Paulo General Hospital";"";"ALL";"ADULT, OLDER_ADULT";"PHASE2";32;"OTHER";"INTERVENTIONAL";"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT";"54326916.4.0000.0068|USP Brazil";"2016-12-01";"2018-02";"2018-03";2016-05-09;NA;2018-05-03;"University of Sao Paulo General Hospital, São Paulo, 05403-000, Brazil";"2018-02";2018;2;TRUE;"2015-2019";"1-99"
"NCT02207088";"Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease";"https://clinicaltrials.gov/study/NCT02207088";"";"COMPLETED";"YES";"Chronic Hepatitis C|Hepatitis C Virus|Compensated Cirrhosis|Severe Renal Impairment|End-stage Renal Disease";"DRUG: ombitasvir/paritaprevir/ritonavir|DRUG: dasabuvir|DRUG: Ribavirin";"Percentage of Participants With Sustained Virologic Response 12 (SVR12) Weeks Post-treatment, SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification (\<LLOQ) 12 weeks after the last dose of study drug., 12 weeks after the last actual dose of study drug";"Percentage of Participants With On-treatment Virologic Failure, On-treatment virologic failure was defined as confirmed HCV RNA ≥ LLOQ after \< LLOQ during treatment, confirmed increase of \> 1 log (subscript)10(subscript) IU/mL above the lowest value post-baseline HCV RNA during treatment, or HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks of treatment., Up to 24 weeks|Percentage of Participants With Post-Treatment Relapse, Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after the last dose of study drug among participants completing treatment and with HCV RNA \< LLOQ at the end of treatment., Within 12 weeks after the last dose of study drug";"";"AbbVie";"";"ALL";"ADULT, OLDER_ADULT";"PHASE3";68;"INDUSTRY";"INTERVENTIONAL";"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT";"M14-226|2014-001527-77";"2014-09-23";"2016-12-06";"2016-12-06";2014-08-01;2017-11-09;2017-11-09;"";"2016-12-06";2016;12;TRUE;"2015-2019";"1-99"
"NCT00321178";"BURULICO Drug Trial Study Protocol: RCT SR8/SR4+CR4, GHANA";"https://clinicaltrials.gov/study/NCT00321178";"BURULICO";"COMPLETED";"NO";"Buruli Ulcer|Mycobacterium Ulcerans";"DRUG: SR4 - switch to CR4";"healing without recurrence and without debridement surgery at 12 months follow-up after start of treatment, 12 months follow-up after start of treatment";"reduction in lesion surface area and/or clinically assessed improvement on completion of treatment, averting the need for debridement surgery, during treatment and follow-up x 12 months|adverse events, during treatment and follow-up x 12 months|functional limitations, at end of follow-up (12 months)";"";"University Medical Center Groningen";"";"ALL";"CHILD, ADULT, OLDER_ADULT";"PHASE2|PHASE3";151;"OTHER";"INTERVENTIONAL";"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT";"BURULICODRUGTRIAL|EU FP6 2003-INCO-Dev2-015476";"2006-05";"2008-01";"2009-02";2006-05-03;NA;2010-06-30;"Agogo Hospital, Agogo, Ashanti Region, Ghana|Nkawie-Toaso Hospital, Nkawie, Ashanti Region, Ghana";"2008-01";2008;1;TRUE;"2005-2009";"100-499"
"NCT05216211";"The Effect of Caudal Block on Optic Nerve Sheath Diameter in Pediatric Patients";"https://clinicaltrials.gov/study/NCT05216211";"";"COMPLETED";"NO";"Postoperative Pain|Intracranial Hypertension";"DRUG: Bupivacaine Hydrochloride";"Optic Nerve Diameter, Consecutive Optic Nerve Sheath Diameter Measurement from Both Eyes, First minute|Optic Nerve Diameter, Consecutive Optic Nerve Sheath Diameter Measurement from Both Eyes, 5th minutes|Optic Nerve Diameter, Consecutive Optic Nerve Sheath Diameter Measurement from Both Eyes, 15th minutes|Optic Nerve Diameter, Consecutive Optic Nerve Sheath Diameter Measurement from Both Eyes, 30th minutes";"";"";"Ataturk University";"";"ALL";"CHILD";NA;60;"OTHER";"INTERVENTIONAL";"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC";"Optic nerve Caudal";"2021-12-09";"2022-09-01";"2022-10-30";2022-01-31;NA;2022-12-23;"Ataturk University School of Medicine, Erzurum, Yakutiye, 25100, Turkey (Türkiye)";"2022-09-01";2022;9;TRUE;"2020-2024";"1-99"
"NCT03754582";"A Study of Intravenous Perampanel in Japanese Participants With Epilepsy";"https://clinicaltrials.gov/study/NCT03754582";"";"COMPLETED";"YES";"Epilepsy|Seizures";"DRUG: Perampanel|DRUG: Perampanel";"Number of Participants With Serious Adverse Events (SAEs), A SAE was defined as any untoward medical occurrence that at any dose: Resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect., Up to 60 days (Pretreatment Phase: up to 28 days, Treatment Phase: up to 4 days, Follow-up Phase: up to 28 days after last dose)|Number of Participants With Adverse Events (AEs), An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the investigational product, any new disease or exacerbation of an existing disease, any deterioration in nonprotocol-required measurements of a laboratory value or other clinical test that resulted in symptoms, a change in treatment, or discontinuation of study drug, recurrence of an intermittent medical condition not present pretreatment, an abnormal laboratory test result was considered an AE if the identified laboratory abnormality led to any type of intervention, withdrawal of study drug, or withholding of study drug, whether prescribed in the protocol or not., Up to 60 days (Pretreatment Phase: up to 28 days, Treatment Phase: up to 4 days, Follow-up Phase: up to 28 days after last dose)|Number of Participants With Markedly Abnormal Clinical Laboratory Parameter Values During Treatment and Follow-up Phase, Up to Day 11 (Treatment Phase: at Day 4, Follow-up Phase: up to 7 days after last dose)|Number of Participants With Abnormal Vital Sign Values During Treatment and Follow-up Phase, Up to 11 days (Treatment Phase: up to 4 days, Follow-up Phase: up to 7 days after the last dose)|Number of Participants With Abnormal Body Weight During Treatment and Follow-up Phase, Up to 11 days (Treatment Phase: up to 4 days, Follow-up Phase: up to 7 days after the last dose)|Number of Participants With Clinically Significant Markedly Abnormal Electrocardiogram (ECG) Value During Treatment and Follow-up Phase, Up to Day 11 (Treatment Phase: at Day 4, Follow-up Phase: up to 7 days after the last dose)";"Mean Seizure Frequency Per Day in Pretreatment Phase, Treatment Phase and Follow-up Phase, Seizure frequency was based on number of seizures per day, calculated as the number of seizures over the entire time interval divided by the number of days in the interval., Up to 39 days (Pretreatment Phase: up to 28 days; Treatment Phase: up to 4 days; Follow-up Phase: up to 7 days after the last dose)|Plasma Concentration of Perampanel Before and After Switching From Oral Perampanel to 30-minute Intravenous Infusions of Perampanel, Pretreatment Phase-Day -1: Pre-dose, 0.5 hours, 1 hours and 1.5 hours post-dose; Treatment Phase-Day 1, Day 2, Day 3 and Day 4: Pre-dose and 0.5 hours after start of intravenous infusions";"";"Eisai Co., Ltd.";"";"ALL";"CHILD, ADULT, OLDER_ADULT";"PHASE2";21;"INDUSTRY";"INTERVENTIONAL";"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT";"E2007-J081-240";"2018-11-27";"2019-12-10";"2019-12-10";2018-11-27;2021-01-05;2021-01-05;"Eisai trial site 5, Kurume, Fukuoka, Japan|Eisai trial site 12, Sapporo, Hokkaido, Japan|Eisai trial site 9, Ōmura, Nagasaki, Japan|Eisai trial site 7, Sayama, Osaka, Japan|Eisai trial site 2, Asaka, Saitama, Japan|Eisai trial site 13, Hamamatsu, Shizuoka, Japan|Eisai trial site 8, Kodaira, Tokyo, Japan|Eisai trial site 10, Hiroshima, Japan|Eisai trial site 6, Kagoshima, Japan|Eisai trial site 1, Niigata, Japan|Eisai trial site 11, Okayama, Japan|Eisai trial site 3, Shizuoka, Japan|Eisai trial site 4, Yamagata, Japan";"2019-12-10";2019;12;TRUE;"2015-2019";"1-99"
"NCT05297942";"Expansion of Abbreviations and Acronyms for Patients";"https://clinicaltrials.gov/study/NCT05297942";"";"COMPLETED";"NO";"Heart Failure";"OTHER: Expansion of Abbreviations and Acronyms";"Overall comprehension, count of the total number of abbreviated or expanded terms comprehended by the each participant, Day 1, at the time of the intervention administration";"";"";"Weill Medical College of Cornell University";"Columbia University";"ALL";"ADULT, OLDER_ADULT";NA;60;"OTHER";"INTERVENTIONAL";"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH";"1804019182";"2020-02-01";"2021-08-31";"2021-08-31";2022-03-28;NA;2022-06-16;"Weill Cornell Medicine, New York, New York, 10065, United States";"2021-08-31";2021;8;TRUE;"2020-2024";"1-99"
"NCT02242760";"P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris";"https://clinicaltrials.gov/study/NCT02242760";"";"COMPLETED";"YES";"Acne Vulgaris";"DRUG: SB204 2%|DRUG: SB204 4%|DRUG: Vehicle Gel";"Absolute Change in Inflammatory Lesion Counts, Change in inflammatory lesion count from Baseline to Week 12, Baseline and Week 12|Absolute Change in Non-inflammatory Lesion Counts, Absolute Change in non-inflammatory lesion count from Baseline to Week 12, Baseline and Week 12|Proportion of Success According to the Dichotomized Investigator Global Assessment [IGA] at End of Treatment, Proportion of subjects at end of treatment achieving IGA of 'clear' or 'almost clear' and a change of at least 2 in the IGA from baseline. The IGA was a static assessment. The assessment was made with the evaluator approximately 3 feet away from the subject; the IGA assessment was to be done prior to the lesion counts. A lower grade is considered to be a better outcome.

Grade 0 = clear (clear skin with no inflammatory or non-inflammatory lesions) Grade 1 = almost clear (few non-inflammatory lesions with no more than rare papules (papules may be resolving and hyperpigmented, though not pink-red) Grade 2 = mild (some non-inflammatory lesions with no more than a few inflammatory lesions) Grade 3 = moderate (up to many non-inflammatory lesions and may have some inflammatory lesions, but no more than 1 nodular lesion) Grade 4= severe (up to many non-inflammatory and inflammatory lesions, including nodular lesions), Baseline and Week 12";"Percent Change in Inflammatory Lesion Count From Baseline to Week 12, The percent change in inflammatory lesion count from Baseline to Week 12, Baseline and Week 12|Percent Change in Non-inflammatory Lesion Count From Baseline to Week 12, The percent change in non-inflammatory lesion count from Baseline to Week 12, Baseline and Week 12|Median Time to Improvement, Median time to a 35% improvement in inflammatory lesion counts (Kaplan-Meier estimate). The full range values presented below are estimates made from the Kaplan-Meier figure., Baseline through Week 12";"";"Novan, Inc.";"";"ALL";"CHILD, ADULT";"PHASE2";213;"INDUSTRY";"INTERVENTIONAL";"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT";"NI-AC202";"2014-11";"2015-06";"2015-08";2014-09-17;2023-05-31;2023-05-31;"Qst acne site #1, Hot Springs, Arkansas, 71913, United States|QST Site #118, Encinitas, California, 92024, United States|QST Site #111, San Diego, California, 92123, United States|QST Site #113, San Diego, California, 92123, United States|QST Site #119, Santa Monica, California, 90404, United States|QST Site #103, Boca Raton, Florida, 33486, United States|QST Site # 110, Pinellas Park, Florida, 33781, United States|QST Site # 116, Newnan, Georgia, 302636, United States|QST Site #117, Louisville, Kentucky, 40202, United States|QST Site #112, Detroit, Michigan, 48202, United States|QST Site #120, Warren, Michigan, 48088, United States|QST Site # 121, Minneapolis, Minnesota, 55432, United States|QST Site #107, New York, New York, 10155, United States|QST Site #108, Rochester, New York, 14623, United States|QST Site #109, Rochester, New York, 14625, United States|QST Site #104, Stony Brook, New York, 11790, United States|QST Site # 102, San Antonio, Texas, 78229, United States|QST Site #106, Salt Lake City, Utah, 84117, United States|QST #105, Lynchburg, Virginia, 24501, United States|QST Site #114, Norfolk, Virginia, 23507, United States";"2015-06";2015;6;TRUE;"2015-2019";"100-499"
"NCT03750383";"Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects";"https://clinicaltrials.gov/study/NCT03750383";"";"COMPLETED";"NO";"RSV Infection";"DRUG: EDP-938|DRUG: EDP-938|DRUG: Cyclosporine|DRUG: Prednisone";"Cmax of EDP-938 with and without coadministration with cyclosporine, Up to 12 days|AUC of EDP-938 with and without coadministration with cyclosporine, Up to 12 days|Cmax of EDP-938 with and without coadministration with prednisone, Up to 21 days|AUC of EDP-938 with and without coadministration with prednisone, Up to 21 days";"Safety measured by adverse events, Up to 21 days";"";"Enanta Pharmaceuticals, Inc";"Pharmaceutical Research Associates";"ALL";"ADULT";"PHASE1";48;"INDUSTRY";"INTERVENTIONAL";"Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE";"EDP 938-002";"2018-11-02";"2018-11-17";"2018-12-13";2018-11-23;NA;2019-02-12;"Pharmaceutical Research Associates, Inc.,, Lenexa, Kansas, 66219, United States";"2018-11-17";2018;11;TRUE;"2015-2019";"1-99"
"NCT00601302";"Bioequivalency Study of Amlodipine Tablets Under Fed Conditions";"https://clinicaltrials.gov/study/NCT00601302";"";"COMPLETED";"NO";"Hypertension|Chronic Stable Angina|Vasospastic Angina";"DRUG: Amlodipine";"Bioequivalence, Baseline, Two period, Twenty-one day washout";"";"";"Roxane Laboratories";"";"ALL";"ADULT";NA;40;"INDUSTRY";"INTERVENTIONAL";"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT";"AMLO-02";"2004-04";"2004-04";"2004-05";2008-01-28;NA;2018-01-23;"Gateway Medical Research, Inc., Saint Charles, Missouri, 63301, United States";"2004-04";2004;4;TRUE;"<2005";"1-99"
"NCT02741297";"VELOCITY: A Study to Characterize Real-World Outcomes of Spinal Cord Stimulation";"https://clinicaltrials.gov/study/NCT02741297";"";"COMPLETED";"YES";"Chronic Pain";"DEVICE: Spinal Cord Stimulation (SCS) System";"Percentage of Low Back Pain Responders, Percentage of low back pain responders at 3 months post-activation with no increase in opioids from Baseline to 3 months post-activation, 3 months";"";"";"Boston Scientific Corporation";"";"ALL";"ADULT, OLDER_ADULT";NA;73;"INDUSTRY";"INTERVENTIONAL";"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT";"91113648";"2016-04-19";"2018-09-21";"2019-06-25";2016-04-18;2020-01-10;2021-01-05;"Schreiber Klinik, München, Germany|Azienda Ospedale Monaldi, Naples, Italy|Ziekenhuis Rijnstate, Velp, Netherlands|Southmead Hospital Bristol, Bristol, United Kingdom|St. Bartholomews Hospital, London, United Kingdom";"2018-09-21";2018;9;TRUE;"2015-2019";"1-99"
"NCT03866811";"Reducing Teen Pregnancy in the Emergency Department";"https://clinicaltrials.gov/study/NCT03866811";"ERICA";"COMPLETED";"YES";"Reproductive Behavior|Sexual Behavior|Adolescent Behavior|Contraception";"BEHAVIORAL: Dr. Erica";"Potential Efficacy: Effective Contraception Initiation Rates [Time Frame: Enrollment, 12 Weeks Post-enrollment (2 Weeks Post Close of Intervention)], Initiation of effective contraception will be considered positive if participant self-reports initiation of effective contraception at follow up (telephone or online survey). An """"effective"""" form of contraception (as defined by the World Health Organization) includes the following:

* intrauterine device
* birth control implant
* birth control patch
* birth control pills or oral contraceptives
* injectable birth control
* a vaginal ring, 3 months";"Feasibility: Percentage of Refusal, Percentage of eligible participants who refused, Baseline|Feasibility: Opt Outs Measured Via Mobile Platform, Percentage of enrolled participants in the intervention group who texted to stop receiving messages., 3 months|Number of Enrolled Participants Who do Not Complete Follow up, Measurement of the feasibility of Dr. Erica among adolescent female users, 3 months|Acceptability: Satisfaction With the Intervention Measured Via Online or Telephone Survey, Percentage of participants in the intervention group who followed up and answered that they like the program and would recommend it to friends, 3 months|Any Sex Over the Past 3 Months, Self-report of any over the past 3 months., 1 year";"Exploratory Efficacy Outcome: Number of Participants Who Followed up for Preventative Reproductive Care, Participants who reported they did not go to the Columbia Family Planning Clinic over the past 3 months and answered """"yes"""" to the question: """"Over the past 3 months, have you seen a doctor for medical care?"""" In this Outcome, """"preventative reproductive care"""" is defined as any visit to a doctor for the purposes of reproductive health., 3 months";"Columbia University";"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)";"FEMALE";"CHILD, ADULT";NA;146;"OTHER";"INTERVENTIONAL";"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION";"AAAR6781 (Part 2)|1K23HD096060-01";"2019-03-03";"2020-07-02";"2020-07-02";2019-03-07;2024-08-06;2024-08-06;"Morgan Stanley Children's Hospital Emergency Department, New York, New York, 10032, United States";"2020-07-02";2020;7;TRUE;"2020-2024";"100-499"
"NCT00555672";"Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer";"https://clinicaltrials.gov/study/NCT00555672";"";"COMPLETED";"YES";"Stomach Neoplasms";"DRUG: 5-fluorouracil|DRUG: cisplatin|DRUG: sunitinib malate";"Number of Participants With First-cycle Dose Limiting Toxicities (DLTs), The incidence of DLTs assessed during the first cycle (21 days)., Cycle 1 (Baseline to Day 21)";"Maximum Observed Plasma Concentration (Cmax), Day 1 of Cycle 1 (2, 4, 6, 8, 10, and 24 hours post dose)|Area Under the Curve From Time 0 to 24 Hours Postdose [AUC (0-24)], Area under the plasma concentration versus time curve from time 0 (pre-dose) to 24 hours postdose (0-24)., Day 1 of Cycle 1 (2, 4, 6, 8, 10, and 24 hours postdose)|Time to Reach Maximum Observed Plasma Concentration (Tmax), Tmax is the time to first occurrence of maximum observed plasma concentration (Cmax)., Day 1 of Cycle 1 (2, 4, 6, 8, 10, and 24 hours post dose)|Steady State Concentration (Css) of 5-Fluorouracil (5-FU), Steady state plasma concentration of 5-FU equals AUC(2-6) divided by 4, where AUC(2-6) is the area under the plasma concentration versus time curve from time 2 to 6 hours postdose (2-6)., Day 1 of Cycle 1 (2, 4, and 6 hours post infusion)|Infusion Rate (Zero Order) (R0) of 5-FU, Infusion rate of 5-FU equals total dose divided by infusion time., Day 1 of Cycle 1 (2, 4, and 6 hours post infusion)|Clearance (CLss) of 5-FU, Steady state total body clearance equals infusion rate (zero order) divided by steady state plasma concentration of 5-FU (R0/Css)., Day 1 of Cycle 1 (2, 4, and 6 hours post infusion)|Area Under the Curve From Time 2 to 6 Hours Postdose [AUC (2-6)] of 5-FU, Area under the plasma concentration versus time curve from time 2 to 6 hours postdose (2-6)., Day 1 of Cycle 1 (2, 4, and 6 hours post infusion)|Number of Participants With Objective Response, Number of participants with an objective response-based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR defined as the disappearance of all target lesions. PR defined as greater than or equal to (≥) 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions., Baseline, Day 21 of every even-numbered cycle up to 15 Months|Duration of Response (DR), Time from the first objective documentation of tumor response (confirmed or partial response) to first documented objective tumor progression or death due to any cause, whichever occurrs first. DR calculated as (Months) equals (the end date for DR minus first subsequent confirmed CR or PR plus 1) divided by 30., Baseline up to Month 15|Progression-Free Survival (PFS), Median time (50%) from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. PFS calculated as (Months) equals (first event date minus first dose date plus 1) divided by 30., Baseline up to Month 15";"";"Pfizer";"";"ALL";"ADULT, OLDER_ADULT";"PHASE1";34;"INDUSTRY";"INTERVENTIONAL";"Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT";"A6181128";"2008-08";"2009-12";"2010-08";2007-11-09;2011-01-05;2011-12-19;"Pfizer Investigational Site, Barcelona, Barcelona, 08003, Spain|Pfizer Investigational Site, L'Hospitalet de Llobregat, Barcelona, 08907, Spain|Pfizer Investigational Site, Madrid, Madrid, 28041, Spain";"2009-12";2009;12;TRUE;"2005-2009";"1-99"
"NCT00547105";"Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer";"https://clinicaltrials.gov/study/NCT00547105";"";"COMPLETED";"YES";"Lung Cancer";"DRUG: Erlotinib|RADIATION: SBRT";"6 Month Progression-Free Survival, For liver lesions treated with SBRT, RECIST (Response Evaluation Criteria in Solid Tumors) criteria will be used for evaluation of progression. Progression (PD) is at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

Evaluation of lung lesions at any time after SBRT is difficult in view of the expected fibrotic reaction. Bone lesions seen only on PET are also not well scored by RECIST criteria and will not be evaluated in that manner. In this study progressive disease (PD) will be defined as residual increased metabolic PET scan in combination with expanded parenchymal opacity that retains mass-like discrete borders and extends outside the volume of lung that received at least 18 Gy., 6 months";"In-field Local Control, In-field local control is defined as number of treated lesions that did not grow in size or increase in metabolic activity., 9 months|Number of Participants Without Serious Adverse Events Related to Radiation, Common Terminology Criteria for Adverse Events v4.03 (CTCAE) is used as the standard classification and severity grading scale for adverse events, 3 years|Overall Survival, evaluate overall survival after SBRT in combination with erlotinib, up to 5 years|Duration of Erlotinib Use and Time to Initiation of Third-line Systemic Therapy, To evaluate the duration of erlotinib usage and time to initiation of third line systemic agent (chemotherapy or biologic agent), 3 years|Out-of-field Disease Progression, Number of Participants with Disease Progression Outside the Radiation treated field at 9 Months, 9 months|Progression-free Survival, For liver lesions treated with SBRT, RECIST (Response Evaluation Criteria in Solid Tumors) criteria will be used for evaluation of progression. Progression (PD) is at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

Evaluation of lung lesions at any time after SBRT is difficult in view of the expected fibrotic reaction. Bone lesions seen only on PET are also not well scored by RECIST criteria and will not be evaluated in that manner. In this study progressive disease (PD) will be defined as residual increased metabolic PET scan in combination with expanded parenchymal opacity that retains mass-like discrete borders and extends outside the volume of lung that received at least 18 Gy., up to 5 years";"";"University of Texas Southwestern Medical Center";"";"ALL";"ADULT, OLDER_ADULT";"PHASE2";24;"OTHER";"INTERVENTIONAL";"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT";"SCCC-0609131|SCCC-042007-003|CDR0000571634";"2007-06-25";"2016-07-06";"2017-07-06";2007-10-22;2018-04-23;2020-08-21;"University of Colorado Cancer Center at UC Health Sciences Center, Aurora, Colorado, 80045, United States|Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, 75390, United States";"2016-07-06";2016;7;TRUE;"2015-2019";"1-99"
"NCT04400552";"Perioperative Oral Nutrition Supplementation in Malnourished Surgical Cancer Patients";"https://clinicaltrials.gov/study/NCT04400552";"";"COMPLETED";"NO";"Cancer of Breast|Cancer Colon";"DIETARY_SUPPLEMENT: ONS Pre-op + ONS Post-op|DIETARY_SUPPLEMENT: ONS Pre-op + ONS Post-op + ONS Post-op 3 months|DIETARY_SUPPLEMENT: Usual intake Pre-op + ONS Post-op";"Change in body weight, Anthropometry measurement, Change from baseline body weight at 4 months|Change in body mass index (BMI), Anthropometry measurement, Change from baseline body mass index (BMI) at 4 months|Change in serum albumin level, Serum albumin is an indicator of protein stores to assess nutritional status, Change from baseline serum albumin level at 4 months|Change in serum pre-albumin level, Serum pre-albumin is an indicator of protein stores to assess nutritional status, Change from baseline serum pre-albumin level at 4 months";"Change in handgrip force, Handgrip force is a measure of handgrip strength by dynamometer, Change from baseline handgrip force at 4 months|Change in muscle mass, Muscle mass reported in kilogram is measured by bioelectrical impedance analyser, Change from baseline muscle mass at 4 months|Change in fat mass, Fat mass reported in kilogram is measured by bioelectrical impedance analyser, Change from baseline fat mass at 4 months|Change in serum transferrin level, Serum transferrin is a measure of nutritional status, Change from baseline serum transferrin level at 4 months|Change in hemoglobin level, Serum hemoglobin is a measure of nutritional status, Change from baseline hemoglobin level at 4 months|Change in high sensitivity c-reactive protein (HsCRP) level, High sensitivity c-reactive protein (HsCRP) is a measure of inflammatory status, Change from baseline high sensitivity c-reactive protein (HsCRP) level at 4 months|Change in Interleukin-6 (IL-6), Interleukin-6 (IL-6) is a measure of inflammatory status, Change from baseline Interleukin-6 (IL-6) at 4 months|Change in salivary cortisol level, Salivary cortisol level is a biological marker of stress reaction, Change from baseline salivary cortisol level at 4 months|Change in energy intake, Energy intake reported in calories is a dietary measure to assess nutritional status, Change from baseline energy intake at 4 months|Change in protein intake, Protein intake reported in gram is a dietary measure to assess nutritional status, Change from baseline protein intake at 4 months|Change in Pittsburgh Sleep Quality Index (PSQI) scores, Pittsburgh Sleep Quality Index (PSQI) scores range from 0-42.Higher scores indicate poorer sleep quality, Change from baseline Pittsburgh Sleep Quality Index (PSQI) scores at 4 months|Presence of post-surgical complications, Post-surgical complications are indicated by presence of wound infection, chest infection and use of antibiotics, responses are either yes or no, Change from baseline post-surgical complications at 3 months|Length of hospital stay, Number of days participants are admitted into the hospital, Up to 5 days";"";"IMU University, Malaysia";"Kotra Pharma (M) Sdn Bhd";"ALL";"ADULT, OLDER_ADULT";NA;91;"OTHER";"INTERVENTIONAL";"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE";"IMU R204/2017";"2018-12-26";"2021-06-30";"2021-06-30";2020-05-22;NA;2021-08-25;"International Medical University, Kuala Lumpur, 57000, Malaysia";"2021-06-30";2021;6;TRUE;"2020-2024";"1-99"
"NCT00821002";"A Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS)";"https://clinicaltrials.gov/study/NCT00821002";"";"COMPLETED";"NO";"Open-Angle Glaucoma|Ocular Hypertension";"DRUG: Latanoprost";"Intraocular pressure change from baseline (mmHg), 6 weeks";"Number of subjects with adverse events, 6 weeks";"";"Mati Therapeutics Inc.";"QLT Inc.";"ALL";"ADULT, OLDER_ADULT";"PHASE2";32;"INDUSTRY";"INTERVENTIONAL";"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT";"PPL GLAU 05";"2009-01";"2009-11";"2009-11";2009-01-12;NA;2013-09-19;"Menlo Park, California, 94025, United States";"2009-11";2009;11;TRUE;"2005-2009";"1-99"
"NCT01605032";"Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma";"https://clinicaltrials.gov/study/NCT01605032";"";"COMPLETED";"YES";"DS Stage I Plasma Cell Myeloma|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma|Refractory Plasma Cell Myeloma";"DRUG: Busulfan|DRUG: Melphalan|DRUG: Bortezomib|PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation|PROCEDURE: Peripheral Blood Stem Cell Transplantation";"Rate of Complete Response as Determined by the IMWG Criteria, Number of patients achieved complete response after the treatment regimen, Day 100";"Overall Response Rate, Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR., Up to day 100|Mortality, Up to day 100|Time-to-progression, From start of treatment to disease progression with deaths, up to 2 years|Progression-free Survival, The progression free survival was assessed over a period of 2 years, 2 years|Overall Survival, The overall survival of patients was measured of a period of 2 years., 2 years";"";"Albert Einstein College of Medicine";"National Cancer Institute (NCI)";"ALL";"ADULT, OLDER_ADULT";"PHASE2";19;"OTHER";"INTERVENTIONAL";"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT";"11-12-434|NCI-2013-01207|11-102|11-12-434|P30CA013330";"2012-02";"2018-03";"2018-03";2012-05-24;2020-08-20;2020-08-20;"Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08903, United States|NYU Cancer Institute, New York, New York, 10016, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10065, United States|Albert Einstein College of Medicine, The Bronx, New York, 10461, United States";"2018-03";2018;3;TRUE;"2015-2019";"1-99"
